Portea Healthcare reported improved financials for the year ended March 2025, with operating revenue rising to ₹160 crore and net loss narrowing sharply to ₹19 crore, reflecting stronger operational control and steady demand for home-based medical services across India.
Revenue growth driven by core home-care services
Portea’s operating revenue grew about 15% year-on-year to ₹160 crore in FY25 from ₹139 crore in FY24. Services — including home nursing, physiotherapy, diagnostics, doctor consultations, medical equipment rentals and trained attendants — accounted for roughly 59% of revenue, contributing around ₹95 crore, up 16%.
The company’s product segment also contributed meaningfully. Sales of medical devices and equipment such as oxygen concentrators, nebulisers and BiPAP machines rose about 14% to ₹56 crore, providing a balanced revenue mix between services and products.
Cost control and unit economics
Total expenses remained broadly flat at approximately ₹179 crore, but Portea made progress on cost optimisation. Employee benefit expense fell 4.5% to ₹52.5 crore, reflecting tighter manpower planning and productivity gains.
Certain expense heads increased: consultancy charges rose about 7% to ₹44 crore, material costs were up 21%, and advertising and promotion spending climbed 25% as the company invested in brand visibility and customer acquisition. Other operational expenses, including legal, professional and finance costs, together exceeded ₹30 crore.
Overall efficiency improved: Portea spent ₹1.12 to generate every ₹1 of operating revenue in FY25, compared with ₹1.29 in FY24 — a meaningful improvement in unit economics.
Profitability and liquidity position
Despite narrower losses, key profitability metrics remain under pressure. FY25 EBITDA margin stood at -6.9% and return on capital employed (ROCE) was negative at around 40%, indicating the company has yet to reach sustainable profitability.
At the end of March 2025, Portea reported ₹1 crore in cash and bank balances and around ₹68 crore in current assets, signalling a modest but stable liquidity position to support near-term operations.
Funding, IPO status and strategic outlook
Portea has raised close to $123 million to date from investors including Accel and Ventureast, funding expansion and technology development. The company received regulatory approval for a ₹1,000 crore initial public offering in 2023 but has not announced a firm timeline for listing, reflecting a cautious approach amid prevailing market conditions.
The FY25 results mirror broader trends in India’s home healthcare sector — rising health awareness, an ageing population and growing preference for at-home care. As competition intensifies, Portea’s continued focus on cost discipline, service-led growth and profitable scaling will be critical to its progress toward financial stability and potential listing plans.
